Genentech to Unveil Obesity Data at ADA 2026

Genentech is poised to reveal new data from its obesity research portfolio at the American Diabetes Association's (ADA) 2026 Scientific Sessions. The biotechnology firm will present updates on its investigational oral GLP-1 receptor agonist, GDC-9413, and its melanocortin-4 receptor (MC4R) agonist, GDC-7817. These presentations underscore Genentech's ongoing efforts to address the complex challenges associated with obesity and related metabolic conditions. The company aims to highlight its advancements in developing novel therapeutic strategies.

Advancing Clinical Programs for Obesity

Genentech is scheduled to showcase initial findings for GDC-9413, an oral GLP-1 receptor agonist, derived from a Phase 1 study. The data will detail the compound's safety profile, tolerability, pharmacokinetic properties, and pharmacodynamic effects in both healthy volunteers and individuals with obesity. This oral formulation represents an effort to provide a more convenient alternative to existing injectable therapies. It could potentially improve patient adherence and access to treatment.

Further insights will be shared regarding GDC-7817, an MC4R agonist, also stemming from a Phase 1 clinical trial. This program explores a distinct mechanism of action, aiming to address obesity through a different biological pathway. The presented data will offer an initial understanding of GDC-7817’s clinical characteristics and potential. These findings contribute to the growing body of research in metabolic health.

Both GDC-9413 and GDC-7817 exemplify diverse approaches within Genentech's strategy to develop new therapies. They target different pathways involved in the regulation of appetite and energy metabolism. The company is actively investigating various avenues to deliver effective and accessible treatment options for a broad patient population. These early-stage programs are foundational to future development.

"Obesity is a complex and progressive disease, and there remains a significant unmet need for effective and convenient treatment options,"

— Dr. Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development at Genentech

Expanding Discovery Efforts in Metabolic Health

Beyond its current clinical-stage assets, Genentech will also introduce a new discovery program focused on obesity and metabolic dysfunction. This initiative explores a novel biological mechanism, indicating a broader strategic commitment to foundational research in this area. The program aims to uncover new therapeutic targets.

Details of this discovery program will be presented, outlining its scientific rationale and preliminary preclinical findings. Such early-stage investigations are critical for identifying and validating potential future therapeutic candidates. This work highlights Genentech's long-term vision and investment in addressing unmet medical needs. It demonstrates an integrated approach to drug development.

The company's active participation at the ADA Scientific Sessions underscores its dedication to advancing the scientific understanding of obesity. These presentations aim to contribute valuable insights into potential new treatment paradigms. They also demonstrate the breadth and depth of Genentech's research and development efforts in metabolic diseases. This engagement fosters scientific dialogue within the medical community.

Genentech's forthcoming presentations at the 2026 ADA Scientific Sessions signify its continued investment in the obesity and metabolic disease sector. By pursuing both advanced clinical candidates and novel discovery programs, the company aims to cultivate a diversified portfolio of treatments. These efforts could ultimately offer new therapeutic avenues for individuals worldwide living with obesity and its associated health complications, potentially influencing future clinical practice.